NeuBase Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of NeuBase Therapeutics generated cash of -$29,011,966, which is less than the previous year. Cash used in financing activities reached the amount of -$257,017 last year. Net change in cash is therefore -$29,740,724.
Cash Flow
| 2013 | -2.68M | 0 | 5.18M |
|---|---|---|---|
| 2014 | -5.36M | -3.51M | 16.97M |
| 2015 | -10.69M | -284.95K | 26.45M |
| 2016 | -15.98M | -14.51K | -150.03K |
| 2017 | -19.29M | 88.45K | 19.45M |
| 2018 | -9.49M | 528.03K | -86.26K |
| 2019 | -2.84M | -685.22K | 13.59M |
| 2020 | -10.71M | -716.82K | 33.10M |
| 2021 | -18.87M | -2.56M | 42.33M |
| 2022 | -29.01M | -471.74K | -257.01K |
NBSE Cash Flow Statement (2013 – 2022)
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 52.89M | 31.99M | 10.31M | 249.6K | 12.80M | 12.54M | 28.69M | 13.22M | 5.12M | 2.63M |
Operating activities | ||||||||||
Net income | -33.77M | -25.40M | -17.38M | -26.95M | -13.23M | -23.81M | -25.76M | -15.19M | -9.13M | -5.65M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.26M | 403.04K | 280.46K | 128.37K | 1.12M | 1.16M | 1.18M | 1.17M | 466.30K | 91.14K |
Stock-based compensation expense | 2.89M | 3.69M | 5.19M | 8.95M | 0 | 1.29M | 2.91M | 4.21M | 2.07M | 0 |
| Deferred income tax benefit | 2.89M | 3.69M | 5.19M | 8.95M | 0 | 1.29M | 2.91M | 4.21M | 2.07M | 0 |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 35.14K | 294.54K | -129.08K | 962.43K | -3.09M | -70.75K | -710.26K | -40.63K | -63.82K | 0 |
Cash generated by operating activities | -29.01M | -18.87M | -10.71M | -2.84M | -9.49M | -19.29M | -15.98M | -10.69M | -5.36M | -2.68M |
Investing activities | ||||||||||
Purchases Of Investments | -14.98M | -59.98M | 0 | 0 | 0 | 0 | 0 | -100K | 0 | 0 |
Investments In Property Plant And Equipment | -471.71K | -1.43M | -716.82K | -552.66K | 0 | -4.83K | -14.51K | -184.95K | -3.50M | 0 |
Acquisitions Net | 471.71K | -1.10M | 0 | -132.56K | 0 | 93.28K | 0 | -100K | -13.78K | 0 |
Cash generated by investing activities | -471.74K | -2.56M | -716.82K | -685.22K | 528.03K | 88.45K | -14.51K | -284.95K | -3.51M | 0 |
Financing activities | ||||||||||
Common Stock Issued | 868 | 42.61M | 33.28M | 13.22M | 145.30K | 19.58M | 1.75M | 26.58M | 16.87M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | -14 | 0 | 0 | 0 | 0 | 10.18M | 0 |
Repayments of term debt | 0 | -8.77K | -349.79K | 0 | -356.26K | 0 | -176.07K | 0 | -164.15K | -71.58K |
Cash used in financing activities | -257.01K | 42.33M | 33.10M | 13.59M | -86.26K | 19.45M | -150.03K | 26.45M | 16.97M | 5.18M |
Net Change In Cash | -29.74M | 20.90M | 21.67M | 10.06M | -9.05M | 254.19K | -16.15M | 15.47M | 8.09M | 2.49M |
Cash at end of period | 23.15M | 52.89M | 31.99M | 10.31M | 3.75M | 12.80M | 12.54M | 28.69M | 13.22M | 5.12M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |